- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 39/40 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum bacterial
Patent holdings for IPC class A61K 39/40
Total number of patents in this class: 924
10-year publication summary
|
80
|
55
|
81
|
67
|
51
|
42
|
44
|
38
|
25
|
7
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| MedImmune, LLC | 487 |
24 |
| Xencor, Inc. | 397 |
24 |
| New York University | 1725 |
15 |
| Research Institute at Nationwide Children's Hospital | 551 |
14 |
| The University of Chicago | 1384 |
13 |
| The Regents of the University of California | 19784 |
12 |
| Regeneron Pharmaceuticals, Inc. | 4211 |
11 |
| Abbvie Inc. | 1795 |
9 |
| Humabs Biomed SA | 121 |
9 |
| MacroGenics, Inc. | 232 |
9 |
| Merus N.V. | 208 |
9 |
| University of Rochester | 1304 |
9 |
| Novartis AG | 10963 |
8 |
| The Regents of the University of Michigan | 4660 |
8 |
| MedImmune Limited | 607 |
8 |
| Genentech, Inc. | 3935 |
7 |
| E. R. Squibb & Sons, L.L.C. | 120 |
7 |
| National Research Council of Canada | 1546 |
7 |
| Oral Health Australia Pty Ltd | 25 |
7 |
| University of Maryland, Baltimore | 1005 |
7 |
| Other owners | 707 |